Arbutus Completes $230M Dutch Auction Tender Offer at $5.00/Share, Retiring 23% of Shares
ABUS sits 33% above its 52-week low of $3.5 on elevated volume (4.3× avg).
Summary
Arbutus completed its $230M Dutch auction tender offer, buying back 46M shares at $5.00 each and retiring ~23% of outstanding shares. The offer was oversubscribed with a ~55% proration factor.
Updates
· Seeking Alpha — Arbutus completed the tender offer, buying back 46 million shares at $5.00 each and retiring about 23% of outstanding stock.
- The buyback was funded by the $178.4 million Moderna settlement.
- The buyback followed an August 21 announcement and formal commencement.
Key Events · Financing and Capital Events · ABUS
-
Tender Offer Completed at $5.00/Share
Arbutus will purchase 46,000,000 shares at $5.00 per share — the low end of the $5.00–$5.75 range — for a total of $230 million.
-
23% Share Count Reduction
Post-offer outstanding shares drop from ~199 million to ~153,275,907, a ~23% reduction that is accretive to remaining shareholders.
-
Offer Oversubscribed with 55% Proration
65,907,215 shares were validly tendered, exceeding the 46M share cap. Auction tenders at or below $5.00 will be prorated at ~55%.
-
Roivant Maintains 19.5% Stake
Roivant Sciences Ltd., the largest shareholder, made a proportionate tender and will retain its ~19.5% ownership position.
Analysis · ABUS · Life Sciences
Arbutus finalized its $230 million modified Dutch auction tender offer, purchasing 46 million shares at $5.00 per share — the low end of the $5.00–$5.75 range. The offer was oversubscribed with 65.9 million shares tendered, resulting in a ~55% proration factor. The buyback retires approximately 23% of outstanding shares, reducing the share count from roughly 199 million to 153 million. Roivant Sciences, the largest holder at 19.5%, participated proportionately and maintains its stake. The low-end pricing and oversubscription indicate strong shareholder demand to exit at $5.00, while the significant share count reduction is accretive for remaining holders.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $4.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $929.1M. The 52-week trading range was $3.50 to $5.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.